Trade Wars & Tariffs

The clean-energy firm is commercializing its tech, securing a 10-year fuel deal in Portugal and deploying rail turbines as it seeks greater market access.

Following a five-year transformation, engineering firm Pond & Company enters a new era under Arlington Capital, signaling strong PE interest in infrastructure.

A new alliance brings rugged, flexible payment hardware to software vendors, aiming to streamline integration and capture the booming unattended market.

As employers pull back coverage for pricey weight-loss drugs, a new partnership offers a flexible way to provide access without breaking the budget.

Two global titans unite as LEGO unveils its first-ever Pokémon sets, targeting adult collectors with premium builds and sparking massive fan excitement.

As the SF Zoo faces a financial crisis, a poll reveals overwhelming public support for a bold plan to replace it with a $350M conservation-focused EcoPark.

AbbVie inks a massive deal for a novel bispecific antibody, aiming to combine it with ADCs and enter the high-stakes race for solid tumor therapies.

Backed by Purolator, a massive network expansion by Williams Pharmalogistics aims to reshape Canada's temperature-controlled medical delivery landscape.

KEY Investment Partners acquires BellRock Brands' portfolio out of receivership, launching MM Brands with Joe Bayern to lead a wellness-focused revival.

BioXcel Therapeutics is pushing its drug IGALMI® for home use, a move that could transform mental healthcare but carries significant financial and safety risks.

Palladyne AI launches its IQ 2.0 software, a low-code platform aiming to overhaul defense manufacturing in line with new government mandates.

Utz Brands posted strong 2025 profit growth and market share gains, overcoming retail inventory issues caused by economic headwinds like SNAP delays.

Following their sold-out 'Corpse Paint' vault, e.l.f. and Liquid Death reunite for a new line of lip balms, proving bizarre marketing is king.

A federal plan for the Colorado River's future ignites fears of 'dramatic cuts' for 20 million Californians and threatens a multi-state legal war.

A federal court blocked Edwards Lifesciences' key acquisition, citing monopoly fears, yet the company's financial outlook surprisingly improves.

As Triumph Financial preps its Q4 2025 results, investors watch to see if its tech investments can deliver on high growth expectations amid a complex freight market.

With drug costs soaring, industry veteran Ritu Malhotra joins Illuminate Rx, promising to disrupt the opaque PBM market. But can transparency truly win?

Eason Technology is betting its future on Chinese real estate with a deal that could dilute shareholders by over 80%. But can it get past the NYSE?

A landmark OECD deal exempts US firms from a new 15% global tax, a major victory for over a million employee-owners whose retirement savings were at risk.

As CEO Brian Stading exits after a massive expansion, Lumos elevates internal leaders, pivoting to operational excellence in a fierce fiber broadband market.